Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018

  • ID: 4515983
  • Report
  • 111 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Incyte Corp
  • IO Biotech ApS
  • Kyowa Hakko Kirin Co Ltd
  • MORE
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018

Summary:

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 36 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin.

This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immuno regulation, and antioxidant activity. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 7, 3, 11 and 4 respectively.

Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Adenocarcinoma, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Alopecia, B-Cell Non-Hodgkin Lymphoma, Brain Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Lung Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Psoriasis, Renal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
  • The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Incyte Corp
  • IO Biotech ApS
  • Kyowa Hakko Kirin Co Ltd
  • MORE
Introduction

Report Coverage

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Eli Lilly and Co

Ensemble Therapeutics Corp

F. Hoffmann-La Roche Ltd

Incyte Corp

Innovent Biologics Inc

IO Biotech ApS

iTeos Therapeutics SA

Jiangsu Hengrui Medicine Co Ltd

Kyowa Hakko Kirin Co Ltd

Luye Pharma Group Ltd

Netherlands Translational Research Center BV

NewLink Genetics Corp

Regen BioPharma Inc

Tempest Therapeutics Inc

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles

AI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-5777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dCellVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1406131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EOS-200271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epacadostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galanal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTI-1090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-2455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-01013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3381916 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-7162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLG-802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-70099 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPST-8844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones

Featured News & Press Releases

Mar 14, 2018 : NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting

Feb 09, 2018 : iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference

Jan 08, 2018 : NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors

Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children

Nov 13, 2017: IO Biotech Presented Posters on Preclinical Studies of Melanoma Drug Candidate IO102 at SITC Annual Meeting

Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod

Oct 12, 2017: IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer

Sep 09, 2017: Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma

Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma

Aug 30, 2017: New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma

Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program

Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG

Jul 10, 2017: NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs

Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain

Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by BeiGene Ltd, H1 2018

Pipeline by BirchBioMed Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by CanBas Co Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Ensemble Therapeutics Corp, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Innovent Biologics Inc, H1 2018

Pipeline by IO Biotech ApS, H1 2018

Pipeline by iTeos Therapeutics SA, H1 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Pipeline by Luye Pharma Group Ltd, H1 2018

Pipeline by Netherlands Translational Research Center BV, H1 2018

Pipeline by NewLink Genetics Corp, H1 2018

Pipeline by Regen BioPharma Inc, H1 2018

Pipeline by Tempest Therapeutics Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BeiGene Ltd
  • BirchBioMed Inc
  • Bristol-Myers Squibb Co
  • CanBas Co Ltd
  • Eli Lilly and Co
  • Ensemble Therapeutics Corp
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Innovent Biologics Inc
  • IO Biotech ApS
  • iTeos Therapeutics SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Luye Pharma Group Ltd
  • Netherlands Translational Research Center BV
  • NewLink Genetics Corp
  • Regen BioPharma Inc
  • Tempest Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll